Ginkgo Bioworks Competitors: Every Synthetic Biology Platform Company (2026)
Ginkgo Bioworks (NYSE: DNA) operates the largest horizontal cell programming platform in synthetic biology. But who are its competitors? This page maps every synbio platform company tracked by synbiointel.com -- 45 companies spanning cell programming foundries, precision fermentation, AI protein design, gene editing, DNA synthesis, and lab infrastructure. 13 are publicly traded, with combined sector funding exceeding $22B.
| Company | Platform Type | Stage | Funding | Public / Private | Founded |
|---|---|---|---|---|---|
| Ginkgo Bioworks | Cell Programming / Foundry | Revenue (Public) | $2.8B+ | Public | 2008 |
| Twist Bioscience | Platform | Revenue (Public) | $900M+ | Public | 2013 |
| Mammoth Biosciences | Gene Editing | Growth Stage | $600M+ | Private | 2017 |
| ArsenalBio | Cell Therapy Platform | Growth Stage | $830M+ | Private | 2019 |
| EvolutionaryScale | AI Protein Design | Growth Stage | $142M+ | Private | 2023 |
| Cradle | AI Protein Design | Growth Stage | $103M+ | Private | 2021 |
| Absci Corporation | Lab Infrastructure | Revenue (Public) | $500M+ | Public | 2011 |
| Solugen | Precision Fermentation | Growth Stage | $600M+ | Private | 2016 |
| Perfect Day | Precision Fermentation | Revenue Stage | $750M+ | Private | 2014 |
| LanzaTech | Precision Fermentation | Revenue (Public) | $600M+ | Public | 2005 |
| Pivot Bio | Agriculture | Revenue Stage | $600M+ | Private | 2010 |
| Benchling | Lab Infrastructure | Revenue Stage | $400M+ | Private | 2012 |
| Synthego | Gene Editing | Growth Stage | $300M+ | Private | 2012 |
| Generate Biomedicines | AI Protein Design | Growth Stage | $700M+ | Private | 2018 |
| bit.bio | Platform | Growth Stage | $200M+ | Private | 2016 |
| Arzeda | AI Protein Design | Growth Stage | $70M+ | Private | 2008 |
| Strand Therapeutics | mRNA Platform | Growth Stage | $200M+ | Private | 2018 |
| Chroma Medicine | Gene Editing | Growth Stage | $260M+ | Private | 2021 |
| Caribou Biosciences | Gene Editing | Revenue (Public) | $400M+ | Public | 2011 |
| Tune Therapeutics | Gene Editing | Growth Stage | $275M+ | Private | 2021 |
| Bolt Threads | Platform | Growth Stage | $500M+ | Private | 2009 |
| MycoWorks | Platform | Growth Stage | $200M+ | Private | 2013 |
| Inari Agriculture | Gene Editing | Growth Stage | $400M+ | Private | 2016 |
| Benson Hill | Agriculture | Growth Stage | $500M+ | Private | 2012 |
| Meatable | Platform | Growth Stage | $100M+ | Private | 2018 |
| Aleph Farms | Platform | Growth Stage | $200M+ | Private | 2017 |
| Nobell Foods | Precision Fermentation | Growth Stage | $120M+ | Private | 2016 |
| Provivi | Agriculture | Growth Stage | $100M+ | Private | 2013 |
| Living Carbon | Platform | Growth Stage | $50M+ | Private | 2019 |
| Synthace | Platform | Growth Stage | $60M+ | Private | 2011 |
| Strateos | Lab Infrastructure | Growth Stage | $60M+ | Private | 2012 |
| Spiber | Precision Fermentation | Revenue Stage | $700M+ | Private | 2007 |
| Ecovative Design | Agriculture | Growth Stage | $120M+ | Private | 2007 |
| Cemvita Factory | Platform | Growth Stage | $40M+ | Private | 2017 |
| Mango Materials | Platform | Growth Stage | $25M+ | Private | 2010 |
| Volta Labs | Platform | Growth Stage | $50M+ | Private | 2018 |
| Senti Biosciences | Cell Therapy Platform | Revenue (Public) | $300M+ | Public | 2016 |
| Zymergen (acquired by Ginkgo) | Lab Infrastructure | Growth Stage | $1B+ | Acquired | 2013 |
| Recursion Pharmaceuticals | Cell Therapy Platform | Revenue (Public) | $1B+ | Public | 2013 |
| Beam Therapeutics | Gene Editing | Revenue (Public) | $700M+ | Public | 2017 |
| Intellia Therapeutics | Gene Editing | Revenue (Public) | $1B+ | Public | 2014 |
| CRISPR Therapeutics | Gene Editing | Revenue (Public) | $1.5B+ | Public | 2013 |
| Editas Medicine | Gene Editing | Revenue (Public) | $700M+ | Public | 2013 |
| Verve Therapeutics | Gene Editing | Revenue (Public) | $600M+ | Public | 2018 |
| Sana Biotechnology | Cell Programming / Foundry | Revenue (Public) | $1B+ | Public | 2018 |
Ginkgo Bioworks faces competition from 44 other synthetic biology platform companies, but no single competitor replicates its horizontal model. Most rivals are vertically integrated -- Perfect Day in dairy proteins, Solugen in industrial chemicals, EvolutionaryScale in AI protein design, CRISPR Therapeutics in gene editing therapies.
The competitive landscape in 2026 is defined by two forces: the rise of AI+biology companies (EvolutionaryScale, Absci, Cradle, Generate Bio) that threaten Ginkgo's wet-lab-first approach, and the scaling challenge in precision fermentation where vertical specialists may achieve commercial economics faster than horizontal platforms.
For investors comparing DNA stock to alternatives, the key question is whether Ginkgo's platform breadth creates durable competitive advantage or whether vertical specialists with deeper domain expertise will capture more value. The answer likely varies by application: Ginkgo's foundry model adds clear value in novel organism engineering, while AI-native companies may dominate protein design.